stonks4u
Log inSign up free
AURX logo

AURX Nuo Therapeutics, Inc.

Other OTC · Biotechnology · Healthcare

$0.77
-0.06 (-7.23%)

Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patie…

Market Cap: $37.27Mwww.nuot.com

Price

No data yet.

Signal Score (90d)

90
90
Aug 17Aug 17

Quote

Day Range
$0.77 – $0.83
52-Week Range
$0.77 – $3.23
Volume
$2.4K
Market Cap
$37.27M
50-Day Avg
$0.96
200-Day Avg
$1.49
Prev Close
$0.83
Open
$0.83

Valuation & Ratios

P/E Ratio
-37.10
EPS
$-0.05
P/B Ratio
-97.44
P/S Ratio
28.13
Debt/Equity
-0.62
Current Ratio
1.06
Dividend Yield
+0.0%
Gross Margin
+66.9%

Returns & Efficiency

Return on Equity
+262.6%
Return on Assets
-136.1%
FCF Yield
-1.2%
EV/EBITDA
-39.52

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$3.31M$-2.51M$-0.05
2024$1.37M$-2.32M$-0.05
2023$608.5K$-3.17M$-0.08
2022$112.3K$-3.03M$-0.08
2021$0.00$-90.7K$-0.00

Social Signal Score

40
5d
41
1 mentions
—
30d
40
1 mentions
—
60d
40
1 mentions
—
90d
40
1 mentions
—
news: 1

Earnings

3of 3 quarters beat consensus

Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Fri, Aug 14$-0.01 vs $-0.01beat
  • Thu, May 14$-0.01 vs $-0.01beat
  • Wed, Feb 25$-0.01 vs $-0.01beat

Estimates and results for AURX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by AURX officers and directors.

Bought
$1.4m

6 trades

Sold
$544k

10 trades

  • Jorden David Emersonsold
    director, officer: CEO/CFO·200,000 @ $1.50·$300k·Nov 28, 2025·filing
  • Sheedy Charles Ebought
    10 percent owner·133,333 @ $1.50·$200k·Jul 30, 2025·filing
  • Sheedy Charles Ebought
    10 percent owner·125,000 @ $0.75·$94k·Sep 18, 2024·filing
  • Sheedy Charles Ebought
    10 percent owner·100,000 @ $0.75·$75k·May 20, 2024·filing
  • Sheedy Charles Ebought
    10 percent owner·150,000 @ $0.50·$75k·Dec 19, 2023·filing
  • Sheedy Charles Ebought
    10 percent owner·62,500 @ $2.00·$125k·Aug 1, 2023·filing
  • Jorden David Emersonsold
    CEO/CFO·30,000 @ $1.50·$45k·Nov 9, 2022·filing
  • Jorden David Emersonsold
    CEO/CFO·30,000 @ $1.50·$45k·Nov 9, 2022·filing

84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

AURXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·6h ago·Negative

    …date D ifferentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth HOUSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the second quarter ended June 30, 2026 and provided an operational and business update. Second Quarter and First Half 2026 Financial Summary Total revenues of app…

    View source ↗